{
  "id": 1714983,
  "title": "Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer",
  "url": "https://urgent.news/2026/08/18/oncolytics-biotech-aligns-with-fda-on-registrational-path-for-second",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-18T13:06:53.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/oncolytics-biotech-aligns-with-fda-on-registrational-path-for-second-line-ras-mutant-mss-colorectal-cancer"
  },
  "original_language": "en",
  "account": null,
  "summary": "FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate and progression-free survival supporting full approval Pivotal expansion to follow initial clinical data from the ongoing randomized Part A SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}